🇺🇸 FDA
Pipeline program

Buprenorphine Extended-Release Injection

INDV-6000-405

Approved small_molecule completed

Quick answer

Buprenorphine Extended-Release Injection for Opioid Use Disorder is a Approved program (small_molecule) at Indivior Pharmaceuticals with 1 ClinicalTrials.gov record(s).

Program details

Company
Indivior Pharmaceuticals
Indication
Opioid Use Disorder
Phase
Approved
Modality
small_molecule
Status
completed

Clinical trials